Noxopharm Ltd. · ASX:NOX
Noxopharm — Non-Deal Roadshow (March 2020)
17 slides from Noxopharm's roadshow presentation, Mar 31, 2020
Slide 1: Noxopharm Virtual Roadshow Corporate Presentation
For personal use only 31 March 2020 Sydney, Australia Noxopharm Virtual Roadshow Corporate Presentation Sydney, 31 March 2020: Noxopharm (ASX: NOX) is pleased to provide shareholders and the market the attached Noxopharm “Corporate Presentation”. This document is being used by Noxopharm for presenta
Slide 2: For personal use only
For personal use only uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. Suite 3, Level 4, 828 Pacific Highway, Gor
Slide 3: Noxopharm Limited Veyonda Non-Deal Roadshow Presentation
March/April 2020 For personal use only Noxopharm Limited Veyonda® Non-Deal Roadshow Presentation DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX For pers
Slide 5: Contents
Contents For personal use only Introduction Investment Highlights Veyonda® Clinical Strategy Commercial Strategy Market Opportunities © 2020 Noxopharm Ltd. All rights reserved.
Slide 6: Introduction
Introduction Technology platform For personal use only q isoflavonoid molecular structure offering new generation of therapeutics built around polypharma actions (tyrosine and serine-threonine kinase inhibition) and restriction to prion-like (abnormal functioning) kinase targets Proprietary IP q str
Slide 7: Investment Case
Investment Case Veyonda® being positioned for the largest sector in the oncology market For personal use only - end-stage cancer where treatment limited to palliative care - little competition - multi-billion $ market opportunity Veyonda® immediate goal is late-stage prostate cancer - estimated 300,
Slide 8: Clinical Strategy for Prostate Cancer
Clinical Strategy for Prostate Cancer Ø Main objective: For personal use only To provide a clinical data package that is attractive for future commercial partners Ø Implementation Steps: ― First Prostate Cancer clinical trial (DARRT-1) has finished and was successful ― Second Prostate Cancer clinica
Slide 9: Which Market Segment does Veyonda occupy?
Which Market Segment does Veyonda occupy? For personal use only Course of Disease and Treatment Journey for Stage I - IV Prostate Cancer Surgery Chemical Androgen Chemo- Palliative therapy and/or local castration & receptor Rising PSA levels in blood therapy radiotherapy therapy inhibitors Veyonda®
Slide 10: Veyonda - What does the Clinical Data show?
1 Veyonda® – What does the Clinical Data show? For personal use only Ø 26 men enrolled with late-stage prostate cancer Ø Metastatic castration-resistant prostate cancer (mCRPC) Ø Progressive disease Ø No remaining standard treatment options Ø Eligible for palliative RT for symptomatic relief Ø Treat
Slide 11: DARRT-1: Does Veyonda work?
11 DARRT-1: Does Veyonda work? Ø In the 15* patients who were evaluable at 6 For personal use only months1 The Tumours stopped growing or reduced in size in 10 patients (1 patient achieved a partial response and 9 achieved stable disease at 6 months) Overall (RECIST1.1) N=10 N=5 N=15 Complete respon
Slide 12: What is the Aim of the next Trial?
2 What is the Aim of the next Trial? Ø Objectives: For personal use only ― The DARRT-2 trial is designed to provide the data that Commercial Partners are looking for ― It also aims to satisfy the Regulatory Authorities Ø Building on the experience and data of DARRT-1 Ø Phase 2 trial; multinational Ø
Slide 13: Additional Opportunity in Prostate Cancer
Additional Opportunity in Prostate Cancer For personal use only External Radiation Internal Radiation Ø Standard-of-Care Ø Experimental Ø Widely used Ø Billion-dollar Acquisition by Novartis DARRT LuPIN © 2020 Noxopharm Ltd. All rights reserved.
Slide 14: LuPIN Trial: Key Interim Results
LuPIN Trial: Key Interim Results v Veyonda® + 177Lu-PSMA-617 For personal use only § Overall Survival (OS) is a measure of the time from the start of treatment until death. 17.1 months ü Median OS was 17.1 months – a remarkable result at this late stage of the disease ü The combination therapy was w
Slide 15: Commercial Strategy
2 Commercial Strategy For personal use only Noxopharm commercial priorities 1. Attract potential partners by continuing DARRT-2 Phase 2 clinical trial to undertake clinical trials to develop planning underway Veyonda® as standard of care in treatment of prostate cancer 2. Develop alliances to streng
Slide 16: Market Opportunity
2 Market Opportunity Prostate cancer market opportunity For personal use only • 33,330 prostate cancer deaths are forecast in the US in 2020* • Potentially all of these patients could benefit from treatment with Veyonda® • The potential global demand of late stage cancer patients for multiple cycles
Slide 17: For further information please visit www.noxopharm.com
For personal use only For further information please visit www.noxopharm.com Veyonda® DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.